The Department of Health and Aged Care has published the public summary documents considered at the July 2023 PBAC meeting. Documents include:
- Cipla’s public summary document for Ardalicip®, biosimilar to AbbVie’s Humira® (adalimumab), which was developed by Alvotech (AVT02);
- Juno Pharmaceuticals’ public summary document for Exarane™ and Exarane Forte™ (Sanofi’s Lovenox®) (enoxaparin); and
- Sun Pharma’s public summary document for Yonsa Mpred® (Janssen’s Zytiga®) (abiraterone and methylprednisolone).